Mayne Pharma Group Limited (ASX:MYX)

Market Cap	185.24M -68.5%
Revenue (ttm)	407.11M -1.6%
Net Income	-83.23M
EPS	-1.05
Shares Out	81.25M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	269,086
Average Volume	608,406
Open	2.280
Previous Close	2.290
Day's Range	2.230 - 2.330
52-Week Range	2.040 - 7.280
Beta	0.98
RSI	42.33
Earnings Date	May 22, 2026

About Mayne Pharma Group

Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women’s health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women’s Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third-party customers. It also distributes specialty pharmaceutical products in the dermatology, women’s health, and in...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 2005
• Employees: 491
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: MYX

Financial Performance

In fiscal year 2025, Mayne Pharma Group's revenue was 408.10 million, an increase of 5.07% compared to the previous year's 388.40 million. Losses were -93.84 million, -46.14% less than in 2024.